Information Provided By: 
Fly News Breaks for November 2, 2018
PCRX
Nov 2, 2018 | 08:55 EDT
Jefferies analyst David Steinberg raised his price target for Pacira Pharmaceuticals to $60 citing the company's "solid" Q3 results and guidance increase. To reflect positive Exparel momentum in the oral surgery setting, the analyst increased his out year revenue estimates by 3% to 7% annually. He notes that his model excludes the potentially positive impact from unbundling in ambulatory surgical centers. Steinberg keeps a Buy rating on Pacira.
News For PCRX From the Last 2 Days
There are no results for your query PCRX
